BlackRock’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,352
| Closed | -$1.25K | – | 5659 |
|
|
2025
Q1 | $1.25K | Sell |
2,352
-2
| -0.1% | -$3 | ﹤0.01% | 5328 |
|
|
2024
Q4 | $12.4K | Hold |
2,354
| – | – | ﹤0.01% | 5160 |
|
|
2024
Q3 | $33.7K | Hold |
2,354
| – | – | ﹤0.01% | 4880 |
|
|
2024
Q2 | $38.1K | Hold |
2,354
| – | – | ﹤0.01% | 4912 |
|
|
2024
Q1 | $238K | Sell |
2,354
-859
| -27% | -$54.3K | ﹤0.01% | 4548 |
|
|
2023
Q4 | $75.8K | Hold |
3,213
| – | – | ﹤0.01% | 4884 |
|
|
2023
Q3 | $64.9K | Sell |
3,213
-84
| -3% | -$1.63K | ﹤0.01% | 4953 |
|
|
2023
Q2 | $85.7K | Sell |
3,297
-2,446
| -43% | -$70K | ﹤0.01% | 4964 |
|
|
2023
Q1 | $119K | Sell |
5,743
-1,209
| -17% | -$27.1K | ﹤0.01% | 4916 |
|
|
2022
Q4 | $142K | Buy |
6,952
+13
| +0.2% | +$245 | ﹤0.01% | 4946 |
|
|
2022
Q3 | $191K | Sell |
6,939
-180
| -3% | -$5.18K | ﹤0.01% | 4991 |
|
|
2022
Q2 | $188K | Sell |
7,119
-31,431
| -82% | -$1.4M | ﹤0.01% | 5049 |
|
|
2022
Q1 | $3.08M | Sell |
38,550
-64
| -0.2% | -$7.91K | ﹤0.01% | 4210 |
|
|
2021
Q4 | $7.87M | Buy |
38,614
+2,209
| +6% | +$551K | ﹤0.01% | 3800 |
|
|
2021
Q3 | $11.8M | Buy |
36,405
+20,093
| +123% | +$5.86M | ﹤0.01% | 3607 |
|
|
2021
Q2 | $4.24M | Buy |
16,312
+11,774
| +259% | +$3.59M | ﹤0.01% | 3945 |
|
|
2021
Q1 | $1.75M | Buy |
+4,538
| New | +$1.83M | ﹤0.01% | 4327 |
|
Other funds holding VINC
BlackRock's VINC Position: Q2 2025 in Review
BlackRock sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 2,352 shares — an estimated $1.25K sold.
BlackRock first reported a position in VINC in Q1 2021 and held it in 17 quarters. The position peaked at $11.8M in Q3 2021. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.
- BlackRock reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- BlackRock sold 2,352 Vincerx Pharma, Inc. Common Stock shares in Q2 2025, an estimated $1.25K.
- BlackRock first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 17 quarters.
- BlackRock's Vincerx Pharma, Inc. Common Stock position peaked at $11.8M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.
Based on BlackRock's 13F filing for Q2 2025, filed 12 Aug 2025.